Ruxolitinib (Taro Pharmaceuticals)

芦可替尼 (Taro Pharmaceuticals)

Report date: 2026/04/09 20:00:21

Base Information

Drug NameRuxolitinib (Taro Pharmaceuticals)
Drug Alias NameRuxolitinib Topical Cream 1.5% (Taro Pharmaceuticals)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK1 inhibitorsTyrosine-protein kinase JAK2 inhibitors
TargetsTyrosine-protein kinase JAK1Tyrosine-protein kinase JAK2
Therapy Area/IndicationsDermatitis, AtopicHidradenitis Suppurativa
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumBulgariaCanada +[10] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesTaro Pharmaceuticals Usa Inc
China Registration ClassN/A

Develop Information

Active CompaniesIncyte CorpTaro Pharmaceuticals Usa Inc
Inactive CompaniesN/A
Active IndicationsDermatitis, AtopicHidradenitis Suppurativa
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A